While these findings suggest that activating MiT/TFE factors, through FLCN depletion, could be beneficial for NAFLD and NASH therapy, our data highlight potential long-term consequences. The gene discussed is FLCN; the disease is metabolic dysfunction-associated steatotic liver disease.